{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:43:08Z","timestamp":1786981388915,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11033-022-07166-x","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T03:02:31Z","timestamp":1643079751000},"page":"2303-2309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Blocking TNF signaling may save lives in COVID-19 infection"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-1559","authenticated-orcid":false,"given":"Vitaly","family":"Ablamunits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lepsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"7166_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr\u00edguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62\u201375. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.06.001 (Epub 2020 Jun 2)","journal-title":"Cytokine Growth Factor Rev"},{"key":"7166_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1465-9921-7-125","volume":"7","author":"S Mukhopadhyay","year":"2006","unstructured":"Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125. https:\/\/doi.org\/10.1186\/1465-9921-7-125","journal-title":"Respir Res"},{"key":"7166_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pharmthera.2017.06.008","volume":"180","author":"R Malaviya","year":"2017","unstructured":"Malaviya R, Laskin JD, Laskin DL (2017) Anti-TNF\u03b1 therapy in inflammatory lung diseases. Pharmacol Ther 180:90\u201398. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.008 (Epub 2017 Jun 19)","journal-title":"Pharmacol Ther"},{"key":"7166_CR4","doi-asserted-by":"publisher","first-page":"2002108","DOI":"10.1183\/13993003.02108-2020","volume":"56","author":"JM Leung","year":"2020","unstructured":"Leung JM, Niikura M, Yang CWT, Sin DD (2020) COVID-19 and COPD. Eur Respir J 56:2002108. https:\/\/doi.org\/10.1183\/13993003.02108-2020","journal-title":"Eur Respir J"},{"key":"7166_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1753466619866096","author":"Y Yao","year":"2019","unstructured":"Yao Y, Zhou J, Diao X, Wang S (2019) Association between tumor necrosis factor-\u03b1 and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. https:\/\/doi.org\/10.1177\/1753466619866096","journal-title":"Ther Adv Respir Dis"},{"key":"7166_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pupt.2007.03.003","volume":"21","author":"S Suissa","year":"2008","unstructured":"Suissa S, Ernst P, Hudson M (2008) TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pharmacol Ther 21:234\u2013238. https:\/\/doi.org\/10.1016\/j.pupt.2007.03.003 (Epub 2007 Apr 11)","journal-title":"Pharmacol Ther"},{"key":"7166_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","volume":"175","author":"SI Rennard","year":"2007","unstructured":"Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J (2007) The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:926\u2013934","journal-title":"Am J Respir Crit Care Med"},{"key":"7166_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Wells AU, Jenkins RG (2020) Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 8:807\u2013815","journal-title":"Lancet Respir Med"},{"key":"7166_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061917","author":"K Lechowicz","year":"2020","unstructured":"Lechowicz K, Drozdzal S, Machaj F, Rosik J, Szostak B, Zegan-Baranska M (2020) COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9061917","journal-title":"J Clin Med"},{"key":"7166_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","volume":"34","author":"A Hanna","year":"2020","unstructured":"Hanna A, Frangogiannis NG (2020) Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther 34:849\u2013863. https:\/\/doi.org\/10.1007\/s10557-020-07071-0 (Epub 2020 Sep 9)","journal-title":"Cardiovasc Drugs Ther"},{"key":"7166_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11906-014-0507-z","volume":"17","author":"C De Miguel","year":"2015","unstructured":"De Miguel C, Rudemiller NP, Abais JM, Mattson DL (2015) Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep 17:507. https:\/\/doi.org\/10.1007\/s11906-014-0507-z","journal-title":"Curr Hypertens Rep"},{"key":"7166_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ni.2343","volume":"13","author":"TD Kanneganti","year":"2012","unstructured":"Kanneganti TD, Dixit VD (2012) Immunological complications of obesity. Nat Immunol 13:707\u2013712","journal-title":"Nat Immunol"},{"key":"7166_CR13","doi-asserted-by":"publisher","first-page":"E769","DOI":"10.1152\/ajpendo.00571.2013","volume":"306","author":"NM Harder-Lauridsen","year":"2014","unstructured":"Harder-Lauridsen NM, Krogh-Madsen R, Holst JJ, Plomgaard P, Leick L, Pedersen BK, Fischer CP (2014) Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 306:E769\u2013E778. https:\/\/doi.org\/10.1152\/ajpendo.00571.2013 (Epub 2014 Jan 28)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"7166_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1084\/jem.163.3.740","volume":"163","author":"PP Nawroth","year":"1986","unstructured":"Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740\u2013745","journal-title":"J Exp Med"},{"key":"7166_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood.V72.1.128.bloodjournal721128","volume":"72","author":"PR Conckling","year":"1988","unstructured":"Conckling PR, Greenberg CS, Weinberg JB (1988) Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 72:128\u2013133","journal-title":"Blood"},{"key":"7166_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.V83.1.152.152","volume":"83","author":"I Schwager","year":"1994","unstructured":"Schwager I, Jungi TW (1994) Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 83:152\u2013160","journal-title":"Blood"},{"key":"7166_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2021.01.005","volume":"200","author":"EM Page","year":"2021","unstructured":"Page EM, Ari\u00ebns RAS (2021) Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res 200:1\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2021.01.005","journal-title":"Thromb Res"},{"key":"7166_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11239-020-02172-x","volume":"50","author":"M Bautista-Vargas","year":"2020","unstructured":"Bautista-Vargas M, Bonilla-Abad\u00eda F, Ca\u00f1as CA (2020) Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombolysis 50:479\u2013483. https:\/\/doi.org\/10.1007\/s11239-020-02172-x","journal-title":"J Thromb Thrombolysis"},{"key":"7166_CR19","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1016\/S0021-9258(18)60636-2","volume":"263","author":"RR Schleef","year":"1988","unstructured":"Schleef RR, Bevilaqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797\u20135803","journal-title":"J Biol Chem"},{"key":"7166_CR20","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","volume":"17","author":"FJ Neumann","year":"1997","unstructured":"Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M et al (1997) Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 17:3399\u20133405","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7166_CR21","doi-asserted-by":"publisher","first-page":"22351","DOI":"10.1073\/pnas.2010229117","volume":"117","author":"S Kang","year":"2020","unstructured":"Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y et al (2020) IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A 117:22351\u201322356. https:\/\/doi.org\/10.1073\/pnas.2010229117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7166_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","volume":"14","author":"M Michaud","year":"2013","unstructured":"Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourhashemi F (2013) Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 14:877\u2013882","journal-title":"J Am Med Dir Assoc"},{"key":"7166_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/rr67","volume":"2","author":"MB Reid","year":"2001","unstructured":"Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269\u2013272. https:\/\/doi.org\/10.1186\/rr67 (Epub 2001 Jul 12)","journal-title":"Respir Res"},{"issue":"3\u20134","key":"7166_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10522-018-9753-9","volume":"19","author":"E Mavrogonatou","year":"2018","unstructured":"Mavrogonatou E, Konstantinou A, Kletsas D (2018) Long-term exposure to TNF-alpha leads human skin fibroblasts to a p38 MAPK- and ROS-mediated premature senescence. Biogerontology 19(3\u20134):237\u2013249. https:\/\/doi.org\/10.1007\/s10522-018-9753-9 (Epub 2018 Mar 26)","journal-title":"Biogerontology"},{"key":"7166_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108464","volume":"216","author":"L Omarjee","year":"2020","unstructured":"Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G (2020) Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clin Immunol 216:108464. https:\/\/doi.org\/10.1016\/j.clim.2020.108464","journal-title":"Clin Immunol"},{"issue":"2","key":"7166_CR26","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2666-7568(20)30068-4","volume":"2","author":"E Bischof","year":"2021","unstructured":"Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M (2021) The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. Lancet Healthy Longev 2(2):e105\u2013e111. https:\/\/doi.org\/10.1016\/S2666-7568(20)30068-4","journal-title":"Lancet Healthy Longev"},{"key":"7166_CR27","doi-asserted-by":"publisher","first-page":"H2459","DOI":"10.1152\/ajpheart.00750.2005","volume":"290","author":"A Giordano","year":"2006","unstructured":"Giordano A, Avellino R, Ferraro P, Romano S, Corcione N, Romano MF (2006) Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am J Physiol Heart Circ Physiol 290:H2459\u2013H2465. https:\/\/doi.org\/10.1152\/ajpheart.00750.2005 (Epub 2006 Jan 20)","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7166_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4062\/biomolther.2012.20.1.043","volume":"20","author":"JW Park","year":"2012","unstructured":"Park JW, Jeon YJ, Lee JC, Ahn SR, Ha SW, Bang SY et al (2012) Destabilization of TNF-alpha mRNA by Rapamycin. Biomol Ther (Seoul) 20:43\u201349. https:\/\/doi.org\/10.4062\/biomolther.2012.20.1.043","journal-title":"Biomol Ther (Seoul)"},{"key":"7166_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.bbi.2020.06.008","volume":"88","author":"TP Cothran","year":"2020","unstructured":"Cothran TP, Kellman S, Singh S, Beck JS, Powell KJ, Bolton CJ et al (2020) A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19. Brain Behav Immun 88:957\u2013958","journal-title":"Brain Behav Immun"},{"key":"7166_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0269881117711708","volume":"31","author":"P Kopschina Feltes","year":"2017","unstructured":"Kopschina Feltes P, Doorduin J, Klein HC, Ju\u00e1rez-Orozco LE, Dierckx RAJO, Moriguchi-Jeckel CM, de Vries EFJ (2017) Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol 31:1149\u20131165. https:\/\/doi.org\/10.1177\/0269881117711708","journal-title":"J Psychopharmacol"},{"key":"7166_CR31","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/ard.2009.107912","volume":"69","author":"J Cavanagh","year":"2010","unstructured":"Cavanagh J, Paterson C, McLean J, Pimlott S, McDonald M, Patterson J et al (2010) Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. Ann Rheum Dis 69:1251\u20131252","journal-title":"Ann Rheum Dis"},{"key":"7166_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jocn.2021.03.010","volume":"88","author":"Y Pashaei","year":"2021","unstructured":"Pashaei Y (2021) Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives? J Clin Neurosci 88:163\u2013172","journal-title":"J Clin Neurosci"},{"key":"7166_CR33","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, Rico MS, Vernet R, Beeker N, Jannot A-S, Neuraz A et al (2021) Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID- 2019: results from an observational study. Mol Psychiatry 26:5199\u20135212","journal-title":"Mol Psychiatry"},{"key":"7166_CR34","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B et al (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26:1636\u20131643","journal-title":"Nat Med"},{"key":"7166_CR35","first-page":"E813","volume":"268","author":"JML Stouthard","year":"1995","unstructured":"Stouthard JML, Romijn JA, van der Poll T, Endert E, Klein S, Bakker PJM et al (1995) Endocrine and metabolic effects of interleukin-6 in humans. Am J Physiol 268:E813\u2013E819","journal-title":"Am J Physiol"},{"key":"7166_CR36","doi-asserted-by":"publisher","first-page":"107018","DOI":"10.1016\/j.intimp.2020.107018","volume":"89","author":"H Hamidreza Samaee","year":"2020","unstructured":"Hamidreza Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P (2020) Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. Int Immunopharmacol 89:107018","journal-title":"Int Immunopharmacol"},{"key":"7166_CR37","unstructured":"Sanofi press release (2020). https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-09-01-07-00-00. Accessed 14 Jan 2022"},{"key":"7166_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000289196","volume":"11","author":"JV Falvo","year":"2010","unstructured":"Falvo JV, Tsytsykova AV, Goldfeld AE (2010) Transcriptional Control of the TNF Gene. Curr Dir Autoimmun 11:27\u201360","journal-title":"Curr Dir Autoimmun"},{"key":"7166_CR39","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1006\/cyto.2000.0697","volume":"12","author":"P Ghezzi","year":"2000","unstructured":"Ghezzi P, Sacco S, Agnello D, Marullo A, Caselli G, Bertini R (2000) Lps induces IL-6 in the brain and in serum largely through TNF production. Cytokine 12:1205\u20131210. https:\/\/doi.org\/10.1006\/cyto.2000.0697","journal-title":"Cytokine"},{"key":"7166_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses 1282:1\u201323. https:\/\/doi.org\/10.1007\/978-1-4939-2438-7_1","journal-title":"Coronaviruses"},{"key":"7166_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1185\/030079903125002757","volume":"20","author":"E Tobinick","year":"2004","unstructured":"Tobinick E (2004) TNF-\u03b1 inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin 20:39\u201340. https:\/\/doi.org\/10.1185\/030079903125002757","journal-title":"Curr Med Res Opin"},{"key":"7166_CR42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13054-020-03158-0","volume":"24","author":"A Stallmach","year":"2020","unstructured":"Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M (2020) Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series. Crit Care 24:444. https:\/\/doi.org\/10.1186\/s13054-020-03158-0","journal-title":"Crit Care"},{"key":"7166_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. COVID-19 Global rheumatology alliance. Ann Rheum 79:859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum"},{"key":"7166_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29639","volume":"4","author":"Z Izadi","year":"2021","unstructured":"Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M et al (2021) Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 4:e2129639. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.29639","journal-title":"JAMA Netw Open"},{"key":"7166_CR45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40744-021-00342-8","volume":"8","author":"M Salesi","year":"2021","unstructured":"Salesi M, Shojaie B, Farajzadegan Z, Salesi N, Mohammadi E (2021) TNF-\u03b1 blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: a case-control study. Rheumatol Ther 8:1355\u20131370","journal-title":"Rheumatol Ther"},{"key":"7166_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa114","volume":"26","author":"A Tursi","year":"2020","unstructured":"Tursi A, Vetrone LM, Papa A (2020) Anti-TNF-\u03b1 agents in inflammatory bowel disease and course of COVID-19. Inflamm Bowel Dis 26:e73. https:\/\/doi.org\/10.1093\/ibd\/izaa114","journal-title":"Inflamm Bowel Dis"},{"key":"7166_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40257-021-00605-8","volume":"22","author":"K Kridin","year":"2021","unstructured":"Kridin K, Schonmann Y, Tzur Bitan D, Damiani G, Peretz A, Weinstein O, Cohen AD (2021) Coronavirus disease COVID-19-associated hospitalization and mortality in patients with psoriasis: a population-based study. Am J Clin Dermatol 22:709\u2013718. https:\/\/doi.org\/10.1007\/s40257-021-00605-8","journal-title":"Am J Clin Dermatol"},{"key":"7166_CR48","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD, Herscovitch M (2006) Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25:6887\u20136899","journal-title":"Oncogene"},{"key":"7166_CR49","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","volume":"79","author":"SC Miller","year":"2010","unstructured":"Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P et al (2010) Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79:1272\u20131280","journal-title":"Biochem Pharmacol"},{"key":"7166_CR50","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.8052854","volume":"265","author":"E Kopp","year":"1994","unstructured":"Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956\u2013959","journal-title":"Science"},{"key":"7166_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3346\/jkms.1999.14.3.231","volume":"14","author":"DM Jue","year":"1999","unstructured":"Jue DM, Jeon KI, Jeong JY (1999) Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. J Korean Med Sci 14:231\u2013238","journal-title":"J Korean Med Sci"},{"key":"7166_CR52","doi-asserted-by":"publisher","first-page":"9631","DOI":"10.1073\/pnas.0504097102","volume":"102","author":"Q Yang","year":"2005","unstructured":"Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy, et al (2005) Cardiac glycosides inhibit TNF-alpha\/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci U S A 102:9631\u20139636","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7166_CR53","doi-asserted-by":"publisher","first-page":"e20201080","DOI":"10.1590\/0001-3765202020201080","volume":"92","author":"E Siniorakis","year":"2020","unstructured":"Siniorakis E, Arvanitakis S, Elkouris M (2020) Cardiac glycosides and COVID-19: would it be a promising therapeutic approach? An Acad Bras Cienc 92:e20201080. https:\/\/doi.org\/10.1590\/0001-3765202020201080","journal-title":"An Acad Bras Cienc"},{"key":"7166_CR54","first-page":"m1252","volume":"368","author":"J Haux","year":"2020","unstructured":"Haux J (2020) Digitalis for coronavirus infection! BMJ 368:m1252","journal-title":"BMJ"},{"key":"7166_CR55","doi-asserted-by":"publisher","first-page":"L1094","DOI":"10.1152\/ajplung.00173.2018","volume":"316","author":"L Amarelle","year":"2019","unstructured":"Amarelle L, Katzen J, Shigemura M, Welch LC, Cajigas H, Peterlanderi C et al (2019) Cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery. Am J Physiol Lung Cell Mol Physiol 316:L1094\u2013L1106","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7166_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.resp.2012.05.016","volume":"183","author":"SKS Sarada","year":"2012","unstructured":"Sarada SKS, Veeramohan HP, Titto M, Saumya S, Chitharanjan M (2012) Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. Respir Physiol Neurobiol 183:26\u201334. https:\/\/doi.org\/10.1016\/j.resp.2012.05.016 (Epub 2012 May 22)","journal-title":"Respir Physiol Neurobiol"},{"key":"7166_CR57","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0002-9440(10)65697-0","volume":"153","author":"MA Hernandez-Presa","year":"1998","unstructured":"Hernandez-Presa MA, Bustos C, Ortego M, Tu\u00f1\u00f3n J, Ortega L, Egido J (1998) ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 153:1825\u20131837","journal-title":"Am J Pathol"},{"issue":"21","key":"7166_CR58","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.3390\/ijms21218038","volume":"21","author":"J Hrenak","year":"2020","unstructured":"Hrenak J, Simko F (2020) Renin-angiotensin system: an important player in the Pathogenesis of acute respiratory distress syndrome. Int J Mol Sci 21(21):8038. https:\/\/doi.org\/10.3390\/ijms21218038","journal-title":"Int J Mol Sci"},{"key":"7166_CR59","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126:1671\u20131681. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317134","journal-title":"Circ Res"},{"key":"7166_CR60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X, Ou M, Bi J et al (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9:757\u2013760. https:\/\/doi.org\/10.1080\/22221751.2020.1746200","journal-title":"Emerg Microbes Infect"},{"key":"7166_CR61","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/14656560902800160","volume":"10","author":"L Pascal","year":"2009","unstructured":"Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D et al (2009) Bortezomib and Waldenstrom\u2019s macroglobulinemia. Expert Opin Pharmacother 10:909\u2013916. https:\/\/doi.org\/10.1517\/14656560902800160","journal-title":"Expert Opin Pharmacother"},{"key":"7166_CR62","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.3390\/ijms21103622","volume":"21","author":"L Longhitano","year":"2020","unstructured":"Longhitano L, Tibullo D, Giallongo C, Lazzarino G, Tartaglia N, Galimberti S et al (2020) Proteasome inhibitors as a possible therapy for SARS-CoV-2. Int J Mol Sci 21:3622. https:\/\/doi.org\/10.3390\/ijms21103622 (PMID: 32443911)","journal-title":"Int J Mol Sci"},{"key":"7166_CR63","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/jcp.23029","volume":"227","author":"R Ciarcia","year":"2012","unstructured":"Ciarcia R, Vitiello MT, Galdiero M, Pacilio C, Iovane V, d\u2019Angelo D et al (2012) Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol 227:2798\u20132803","journal-title":"J Cell Physiol"},{"key":"7166_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","volume":"37","author":"E Weisberg","year":"2020","unstructured":"Weisberg E, Parent A, Yang PL, PL, Sattler M, Liu Q, et al (2020) Repurposing of kinase inhibitors for treatment of COVID-19. Pharm Res 37:167. https:\/\/doi.org\/10.1007\/s11095-020-02851-7 (PMID: 32778962)","journal-title":"Pharm Res"},{"key":"7166_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108518","volume":"218","author":"A Morales-Ortega","year":"2020","unstructured":"Morales-Ortega A, Bernal-Bello D, Llarena-Barroso C, Frutos-P\u00e9rez B, Duarte-Mill\u00e1n M\u00c1, Garc\u00eda de Viedma-Garc\u00eda V et al (2020) Imatinib for COVID-19: a case report. Clin Immunol 218:108518. https:\/\/doi.org\/10.1016\/j.clim.2020.108518 (Epub 2020 Jun 27)","journal-title":"Clin Immunol"},{"key":"7166_CR66","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784\u2013803","journal-title":"Pharmacol Res"},{"key":"7166_CR67","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME et al (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:318\u2013328 (Epub 2016 Mar 10)","journal-title":"Clin Exp Rheumatol"},{"key":"7166_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","volume":"17","author":"S Hanauer","year":"2019","unstructured":"Hanauer S, Panaccione R, Danese S, Cheifez A, Reinisch W, Higgins PDR et al (2019) Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol 17:139\u2013147. https:\/\/doi.org\/10.1016\/j.cgh.2018.07.009 (Epub 2018 Sep 10)","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7166_CR69","doi-asserted-by":"publisher","first-page":"5617431","DOI":"10.1155\/2019\/5617431.eCollection2019","volume":"2019","author":"Y Li","year":"2019","unstructured":"Li Y, Yuan L, Yang J, Lei Y, Zhang H, Xia L et al (2019) Changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis. Mediators Inflamm 2019:5617431. https:\/\/doi.org\/10.1155\/2019\/5617431.eCollection2019","journal-title":"Mediators Inflamm"},{"key":"7166_CR70","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/art.37691","volume":"64","author":"A Yarilina","year":"2012","unstructured":"Yarilina A, Xu K, Chan C, Ivashkiv LB (2012) Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum 64:3856\u20133866. https:\/\/doi.org\/10.1002\/art.37691","journal-title":"Arthritis Rheum"},{"key":"7166_CR71","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Tse CLY, Burry L, Dresser LD (2020) Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 40:843\u2013856. https:\/\/doi.org\/10.1002\/phar.2438 (Epub 2020 Jul 27)","journal-title":"Pharmacotherapy"},{"key":"7166_CR72","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P et al (2020) Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 81:647\u2013679. https:\/\/doi.org\/10.1016\/j.jinf.2020.06.052 (Epub 2020 Jun 24)","journal-title":"J Infect"},{"key":"7166_CR73","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Can\u00e8 S et al (2020) Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest 130:6409\u20136416. https:\/\/doi.org\/10.1172\/JCI141772","journal-title":"J Clin Invest"},{"key":"7166_CR74","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19?utm_medium=email&utm_source=govdelivery. Accessed 14 Jan 2022"},{"key":"7166_CR75","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO et al (2021) STOP-COVID Trial Investigators. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 385:406\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa2101643","journal-title":"N Engl J Med"},{"key":"7166_CR76","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M et al (2020) Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395:1407\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(20)30858-8","journal-title":"Lancet"},{"key":"7166_CR77","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","volume":"2","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Richards D, Tanner HL, Feldmann M (2020) Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2:e653\u2013e655. https:\/\/doi.org\/10.1016\/S2665-9913(20)30309-X","journal-title":"Lancet Rheumatol"},{"key":"7166_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medj.2020.11.005","volume":"1","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S et al (2020) The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med (NY) 1:90\u2013102. https:\/\/doi.org\/10.1016\/j.medj.2020.11.005","journal-title":"Med (NY)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07166-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07166-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07166-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T02:41:12Z","timestamp":1645497672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07166-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7166"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07166-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Vitaly Ablamunits and Christopher Lepsy are employed by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript has been internally reviewed and approved at Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Both authors gave their consent to publish the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}